Bharat Immunologicals Quarterly Results for Trading Insights
In 2026, Bharat Immunologicals (BIBCL) reported revenue ₹9 Cr and net profit ₹-18 Cr. View BIBCL yearly price range for the annual high/low range and current price position.
BIBCL Quarterly Results — Revenue, Profit & EPS Highlights
Bharat Immunologicals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Bharat Immunologicals screener.
- Revenue of ₹47 Cr in March 2023 (+0.0% vs March 2023, -41.2% vs March 2022)
- Net Profit of ₹-17 Cr in March 2023 (+0.0% vs March 2023, -88.9% vs March 2022)
- EBITDA of ₹-16 Cr in March 2023 (+0.0% vs March 2023)
- Operating Margin of -41.0% in March 2023 (+0.0pp vs March 2023)
- Earnings Per Share of ₹-3.95 in March 2023 (+0.0% vs March 2023)
Bharat Immunologicals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BIBCL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2023 | March 2022 | March 2021 | March 2020 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 9 | 47 | 80 | 87 | 68 | -80.9% | - |
| Net Profit (₹ Cr) | -18 | -17 | -9 | -18 | -10 | - | - |
| EBITDA (₹ Cr) | -17 | -16 | -4 | -19 | -9 | - | - |
| EPS (₹) | -4.20 | -3.95 | -2.03 | 1.10 | -2.36 | - | - |
| Operating Margin (%) | -13.0% | -41.0% | -6.0% | -24.0% | -16.0% | - | - |
BIBCL Share Price Trend — 1-Year Movement Across Quarterly Results
Bharat Immunologicals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse BIBCL shareholder distribution to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BIBCL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bharat Immunologicals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹455,633.71 Cr | 1840.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.8 |
|
Divis Laboratories
Mar 2026 |
₹247,283.98 Cr | 9322.0 | 2,986 | 751 | -5.0% | - | 25.2% | 329.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4965.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.4 |
|
Zydus Life Science
Mar 2026 |
₹116,411.21 Cr | 1119.1 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.5 |
|
Cipla
Mar 2026 |
₹110,351.67 Cr | 1366.0 | 6,612 | 543 | -9.3% | - | 8.2% | 198.8 |
All amounts in ₹ Crores